NCT05559606View on ClinicalTrials.gov

An OS to Evaluate the Safety & Efficacy of Fixed Dose Combination Therapy With Atorvastatin and Ezetimibe

CompletedOBSERVATIONAL
Enrollment

1,839

Participants

Timeline

Start Date

September 7, 2022

Primary Completion Date

July 30, 2025

Study Completion Date

July 30, 2025

Conditions
Primary Hypercholesterolemia
Trial Locations (1)

Unknown

Severance Hospital, Yonsei University Health System, Seoul

Sponsors
All Listed Sponsors
lead

Boryung Pharmaceutical Co., Ltd

INDUSTRY

NCT05559606 - An OS to Evaluate the Safety & Efficacy of Fixed Dose Combination Therapy With Atorvastatin and Ezetimibe | Biotech Hunter | Biotech Hunter